Faculty Profiles - TAKEICHI Takuya

Papers - TAKEICHI Takuya

Division display 1 - 20 of about 227 ／ All the affair displays >>

Expanding the Relevance of Anti-Ki/SL beyond SLE to Systemic Sclerosis and Dermatomyositis in In-house ELISA Analyses. Reviewed International journal

Koizumi H, Muro Y, Yamashita Y, Ogawa-Momohara M, Kamiya S, Akashi N, Noda E, Takeichi T, Akiyama M

Clinical and experimental dermatology 2025.4

A Case of DPP-4 Inhibitor-Associated Bullous Pemphigoid With Anti-LAD-1 IgG Antibodies Arising From a Post-Traumatic Scar. Reviewed International journal

Sasamoto M, Ogawa-Momohara M, Ishii N, Takeichi T, Muro Y, Akiyama M

International journal of dermatology 2025.4

Estimating the proportions of allele frequencies for SERPINA12 pathogenic variants in Japanese patients with Nagashima-type palmoplantar keratosis/keratoderma. Reviewed International journal Open Access

Aoi Ebata, Takuya Takeichi, Kazuki Nishida, Basile Chretien, Akira Miyazaki, Takenori Yoshikawa, Yuika Suzuki, Kana Tanahashi, Ryo Fukaura, Mariko Seishima, Yasushi Suga, Yoshinao Muro, Yuka Nakazawa, Tomoo Ogi, Masashi Akiyama

The British journal of dermatology 2025.3

Occurrence of bullous pemphigoid during long-term maintenance treatment for pemphigus vulgaris in remission Reviewed International journal

Goto, A; Takeichi, T; Ishii, N; Yamashita, Y; Ogawa-Momohara, M; Muro, Y; Akiyama, M

JOURNAL OF DERMATOLOGY 2025.3

Cutaneous inflammation with upregulated interleukin-36γ and TNFα in a patient with loricrin keratoderma Reviewed

Maki, T; Murakami, M; Takeichi, T; Noda, T; Tanahashi, K; Mitsuma, T; Muro, Y; Akiyama, M

JOURNAL OF DERMATOLOGY 2025.3

Alopecia universalis and type 1 diabetes mellitus both successfully controlled with baricitinib in a patient with autoimmune polyglandular syndrome type 3A. Reviewed International journal

Ayane Goto, Yuta Yamashita, Jun Yuasa, Satoshi Kamiya, Norika Akashi, Haruka Koizumi, Mariko Ogawa-Momohara, Takuya Takeichi, Yoshinao Muro, Masashi Akiyama

The Journal of dermatology 2025.3

Dupilumab treatment decreases expression of microRNAs related to B cell activation in peripheral blood mononuclear cells of atopic dermatitis patients. Reviewed International journal

Kenichiro Matsui, Mariko Ogawa-Momohara, Akira Yokoi, Takuya Takeichi, Kosuke Yoshida, Masami Kitagawa, Tomoki Taki, Chiaki Murase, Yoshinao Muro, Masashi Akiyama

Journal of dermatological science 2025.2

Expanding the SLURP1 disease spectrum: From mal de Meleda to palmoplantar keratoderma/progressive symmetric erythrokeratoderma. Invited Reviewed International coauthorship International journal

Takeichi T, Hsu CK

The British journal of dermatology 2025.2

Concurrent wild-type transthyretin amyloidosis and psoriasis vulgaris in an elderly man. Reviewed International journal

Yasuko Fujii, Takuya Takeichi, Yuta Yamashita, Takahiro Okumura, Ayako Sakakibara, Yoshinao Muro, Masashi Akiyama

The Journal of dermatology 2025.2

Nonsense Variant in CYP4F22 Causes Malformation of Corneocyte Lipid Envelopes in a Lamellar Ichthyosis Patient. Reviewed International journal

Ryo Fukaura, Kana Tanahashi, Michiya Omi, Takuya Takeichi, Masashi Akiyama

Acta dermato-venereologica Vol. 105 page： adv41072 2025.2

Hyperactivation of the IL-17 Axis and IL-36 Signaling in Card14-Mutant Pityriasis Rubra Pilaris Mouse Model. Reviewed International journal

Takenori Yoshikawa, Takuya Takeichi, Tetsuya Hirabayashi, Yoshinao Muro, Yuki Miyasaka, Tamio Ohno, Masashi Akiyama

The Journal of investigative dermatology Vol. 145 ( 2 ) page： 427 - 432 2025.2

Selumetinib for symptomatic, inoperable plexiform neurofibromas in pediatric patients with neurofibromatosis type 1: the first single-center real-world case series in Japan. Reviewed International journal

Yoshihiro Nishida, Norie Nonobe, Hiroyuki Kidokoro, Taichi Kato, Takuya Takeichi, Kunihiro Ikuta, Hiroshi Urakawa, Tomohisa Sakai, Hiroshi Koike, Takeo Fujito, Shiro Imagama

Japanese journal of clinical oncology 2025.1

Language：English Publishing type：Research paper (scientific journal)

OBJECTIVE: In Japan, selumetinib is used in pediatric patients with neurofibromatosis type 1 (NF1) and symptomatic inoperable plexiform neurofibroma (PN). However, there have been no real-world reports on Japanese patients. In this study, we reported a single-center, short-term experience with selumetinib after its approval in Japan. METHODS: We prospectively collected data from 11 pediatric NF1 patients with symptomatic, inoperable PN who were initiated on selumetinib between November 2022 and May 2023; the selumetinib was administered by the same physician. Various patient factors, tumors, dose and efficacy of selumetinib, and adverse events (AE) were investigated. RESULTS: Of 11 patients included, 7 were male, with a mean age of 14 years. The sites of symptomatic main PN included the head and neck, pelvis to lower extremities, and paraspinal lesions in five, three, and three patients, respectively. The median maximum diameter of the main PN was 91 mm, and the median follow-up duration was 19 months. All patients with pain or motor dysfunction experienced symptom improvement after treatment, and the tumors tended to shrink in 7 of the 11 patients (64%). Among the six patients with disfigurements, only one experienced improvement. Of 59 AEs observed, 58 (98%) were grades 1 and 2, and 5 patients (46%) underwent temporary selumetinib withdrawal due to AEs. One patient discontinued the drug (9%) because of rash dermatitis. CONCLUSIONS: Despite the relatively short-term results, no serious AEs were observed, and many patients benefited from selumetinib treatment. In some patients, administration was discontinued or interrupted because of the balance between benefits and AEs, and further data are needed to better understand the general safety and efficacy of selumetinib.

DOI： 10.1093/jjco/hyae184

Web of Science

PubMed

Anti-SS-B antibody seroconversion occurring simultaneously with exacerbation of pulmonary arterial hypertension in a patient with primary Sjögren's syndrome in long-term remission. Reviewed International journal

Eori Noda, Mariko Ogawa-Momohara, Yoshihisa Nakano, Yuta Yamashita, Norika Akashi, Satoshi Kamiya, Haruka Koizumi, Takuya Takeichi, Yoshinao Muro, Masashi Akiyama

European journal of dermatology : EJD Vol. 35 ( 1 ) page： 61 - 63 2025.1

Predictive Value of Anti-SMN Complex Antibodies for Monitoring Cardiopulmonary Complications in MCTD: Insights From an ELISA Study Using Recombinant Gemin4 and an Anti-Nuclear Antibody Test. Reviewed International journal

Haruka Koizumi, Yoshinao Muro, Satoshi Kamiya, Norika Akashi, Yuta Yamashita, Mariko Ogawa-Momohara, Takuya Takeichi, Masashi Akiyama

International journal of rheumatic diseases Vol. 28 ( 1 ) page： e70089 2025.1

Generalized acrodermatitis continua of Hallopeau with an IL36RN variant successfully treated with bimekizumab. Reviewed International journal

Takenori Yoshikawa, Takuya Takeichi, Ryo Fukaura, Soichiro Ikeya, Masashi Akiyama

The Journal of dermatology Vol. 51 ( 12 ) page： e449 - e451 2024.12

【すぐに役立つ　すごく役立つ　皮膚科検査の基本マニュアル】遺伝学的検査・細胞解析　角化異常症(魚鱗癬)における遺伝子異常とその診断

後藤文音, 武市拓也

皮膚病診療 2024.12

【乾癬再考-治療の前に-】(Part1.)乾癬様病態　(総説3)乾癬・乾癬類縁疾患と関連遺伝子のバリアント

野口晴香, 武市拓也

Visual Dermatology 2024.12

Improvement of Skin Lesions in an Adult with CHILD Syndrome Treated with 2% Ketoconazole Cream Reviewed International journal

Michiya O., Tanahasi K., Takeichi T., Akiyama M.

Acta dermato-venereologica Vol. 104 2024.11

Measurement of clinical outcomes of Netherton syndrome following treatment with upadacitinib. Reviewed International journal

Chiaki Murase, Ryo Fukaura, Naoto Yamada, Natsuno Konishi-Izuchi, Hidesada Adachi, Tomoki Taki, Shinya Hara, Takuya Takeichi, Masashi Akiyama

The Journal of dermatology Vol. 51 ( 11 ) page： e399 - e401 2024.11

Biomarkers and patient-related factors associated with clinical outcomes in dupilumab-treated atopic dermatitis. Reviewed International journal

Makiko Kido-Nakahara, Daisuke Onozuka, Kenji Izuhara, Hidehisa Saeki, Satoshi Nunomura, Motoi Takenaka, Mai Matsumoto, Yoko Kataoka, Rai Fujimoto, Sakae Kaneko, Eishin Morita, Akio Tanaka, Michihiro Hide, Tatsuro Okano, Tomomitsu Miyagaki, Natsuko Aoki, Kimiko Nakajima, Susumu Ichiyama, Kyoko Tonomura, Yukinobu Nakagawa, Risa Tamagawa-Mineoka, Koji Masuda, Takuya Takeichi, Masashi Akiyama, Yozo Ishiuji, Michie Katsuta, Yuki Kinoshita, Chiharu Tateishi, Aya Yamamoto, Akimichi Morita, Haruna Matsuda-Hirose, Yutaka Hatano, Hiroshi Kawasaki, Keiji Tanese, Mamitaro Ohtsuki, Koji Kamiya, Yudai Kabata, Riichiro Abe, Hiroshi Mitsui, Tatsuyoshi Kawamura, Gaku Tsuji, Masutaka Furue, Norito Katoh, Takeshi Nakahara

The journal of allergy and clinical immunology. Global Vol. 3 ( 4 ) page： 100317 - 100317 2024.11

Language：English Publishing type：Research paper (scientific journal)

BACKGROUND: Atopic dermatitis (AD) is a common chronic eczematous skin disease with severe pruritus. Several new therapeutic agents for AD such as dupilumab, an anti-IL-4Rα antibody, have been developed in recent years. We need to predict which agent is the best choice for each patient, but this remains difficult. OBJECTIVE: Our aim was to examine clinical background factors and baseline biomarkers that could predict the achievement of improved clinical outcomes in patients with AD treated with dupilumab. METHODS: A multicenter, prospective observational study was conducted on 110 patients with AD. The Eczema Area and Severity Index was used as an objective assessment, and the Patient-Oriented Eczema Measure and Numerical Rating Scale for Pruritus were used as patient-reported outcomes. In addition, some clinical background factors were evaluated. RESULTS: The achievement of an absolute Eczema Area and Severity Index of 7 or less was negatively associated with current comorbidity of food allergy and baseline serum lactate dehydrogenase (LDH) levels. There were negative associations between achievement of a Patient-Oriented Eczema Measure score of 7 or less and duration of severe AD and between achievement of an itching Numerical Rating Scale for Pruritus score of 1 or less and current comorbidity of allergic conjunctivitis or baseline serum periostin level. Furthermore, signal detection analysis showed that a baseline serum LDH level less than 328 U/L could potentially be used as a cutoff value for predicting the efficacy of dupilumab. CONCLUSION: Baseline biomarkers such as LDH and periostin and clinical background factors such as current comorbidity of food allergy and a long period of severe disease may be useful indicators when choosing dupilumab for systemic treatment for AD, as they can predict the efficacy of dupilumab.

DOI： 10.1016/j.jacig.2024.100317

Scopus

PubMed

　 PREV - NEXT 　

<TAKEICHI Takuya>

Papers - TAKEICHI Takuya